The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 13, 2017
Filed:
Mar. 12, 2014
Applicant:
Bristol-myers Squibb Company, Princeton, NJ (US);
Inventors:
James Aaron Balog, Lambertville, NJ (US);
Audris Huang, New Hope, PA (US);
Bin Chen, Lambertville, NJ (US);
Libing Chen, Newtown, PA (US);
Steven P. Seitz, Swarthmore, PA (US);
Amy C. Hart, Ewing, NJ (US);
Jay A. Markwalder, Lahaska, PA (US);
Assignee:
Bristol-Myers Squibb Company, Princeton, NJ (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/135 (2006.01); A61K 31/196 (2006.01); C07C 255/44 (2006.01); C07C 255/57 (2006.01); C07D 213/84 (2006.01); C07C 275/42 (2006.01); C07D 317/66 (2006.01); C07C 311/51 (2006.01); C07D 239/42 (2006.01); C07D 241/42 (2006.01); C07D 257/04 (2006.01); C07D 261/08 (2006.01); C07C 233/55 (2006.01); C07D 261/14 (2006.01); C07C 235/38 (2006.01); C07D 271/12 (2006.01); C07D 213/56 (2006.01); A61K 31/18 (2006.01); A61K 31/216 (2006.01); A61K 31/27 (2006.01); A61K 31/36 (2006.01); A61K 31/41 (2006.01); A61K 31/42 (2006.01); A61K 31/4245 (2006.01); A61K 31/44 (2006.01); A61K 31/498 (2006.01); A61K 31/505 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); C07C 69/743 (2006.01); C07C 271/28 (2006.01); C07C 311/47 (2006.01); C07D 213/75 (2006.01);
U.S. Cl.
CPC ...
A61K 31/196 (2013.01); A61K 31/18 (2013.01); A61K 31/216 (2013.01); A61K 31/27 (2013.01); A61K 31/36 (2013.01); A61K 31/41 (2013.01); A61K 31/42 (2013.01); A61K 31/4245 (2013.01); A61K 31/44 (2013.01); A61K 31/498 (2013.01); A61K 31/505 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); C07C 69/743 (2013.01); C07C 233/55 (2013.01); C07C 235/38 (2013.01); C07C 255/44 (2013.01); C07C 255/57 (2013.01); C07C 271/28 (2013.01); C07C 275/42 (2013.01); C07C 311/47 (2013.01); C07C 311/51 (2013.01); C07D 213/56 (2013.01); C07D 213/75 (2013.01); C07D 213/84 (2013.01); C07D 239/42 (2013.01); C07D 241/42 (2013.01); C07D 257/04 (2013.01); C07D 261/08 (2013.01); C07D 261/14 (2013.01); C07D 271/12 (2013.01); C07D 317/66 (2013.01); C07B 2200/07 (2013.01); C07C 2101/02 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01); C07C 2102/42 (2013.01);
Abstract
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.